SHPH
Shuttle Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.72
−7.09%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.07
From 52W high−73.78%
Volume14595.00
Market cap$22.49M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$5.07
From 52W high
−73.78%
Volume
14595.00
Market cap
$22.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
P/E (TTM)
—
RSI (14)
55.7
MomentumView details →
1D Return
−7.09%
YTD Return
+177.14%
SummaryUpdated Jun 1, 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Rockville, Maryland. The company went public in August 2022 and focuses on developing specialized cancer treatments that enhance the effectiveness of radiation therapy. Shuttle Pharmaceuticals operates through its subsidiary, Shuttle Pharmaceuticals, Inc., and is currently advancing two key drug candidates through clinical trials to address some of the most challenging cancer types including brain tumors, sarcomas, and pancreatic cancer.
Similar companies
Latest newsMore news →
Shuttle Pharmaceuticals Holdings, Inc. amended its 8-K to correct the number of pre-funded warrants issued to 9,741,751 shares of Common Stock as of September 9, 2026, down from the previously reported approximately 16,932,508.25d agoShuttle Pharmaceuticals Holdings, Inc. issued shares of common stock upon conversion of its Series B-1 and B-2 Preferred Stock and issued warrants and pre-funded warrants to purchase common stock in an unregistered private placement.34d agoShuttle Pharmaceuticals Holdings, Inc. amended its merger agreement with United Dogecoin Inc., reducing the number of Mining Rigs required to satisfy the Milestone Event from 2,000 to 500.48d ago